Isoquercetin dosing and patient profiling to lower clot risk in cancer
Isoquercetin as a PDI inhibitor: dose-optimization and patient phenotyping
This work looks at different doses of the plant compound isoquercetin to reduce dangerous blood clots in people with advanced cancer and to find which patients benefit most.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11319724 on NIH RePORTER |
What this research studies
If you join, you would receive isoquercetin at one of several dosing schedules while doctors monitor blood tests and safety measures. The team will measure clot-related markers like D-dimer and collect detailed health and tumor information to profile participants. Researchers will use pharmacodynamic modeling and these patient data to pick the best dose and identify characteristics linked to benefit. Findings will guide a later, larger trial and aim to reduce clot risk without increasing bleeding.
Who could benefit from this research
Good fit: Adults with advanced cancer who are at high risk for venous thromboembolism and meet the study's eligibility and safety criteria are the intended participants.
Not a fit: People without cancer, those not at elevated clot risk, or patients with active bleeding or very high bleeding risk are unlikely to benefit from this project.
Why it matters
Potential benefit: If successful, this could provide a better-tolerated way to lower venous clot risk in people with cancer without increasing bleeding.
How similar studies have performed: A prior phase 2 trial showed a significant drop in circulating D-dimer consistent with antithrombotic activity and extensive preclinical work supports the approach, but optimal dosing has not yet been established.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Zwicker, Jeffrey — Sloan-Kettering Inst Can Research
- Study coordinator: Zwicker, Jeffrey
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.